Director Marshall Centre for Infectious Diseases Research and Training; Clinical Professor;
A medical pioneer whose work transcends all boundaries
Education and Training
2011 Introduction to Mathematical Models of the Epidemiology & Control of Infectious Diseases (Imperial College London)
2010- Mandarin language course (Confucius Institute, UWA)
1985-6 NHMRC Research Fellow; Gastroenterology (Royal Perth Hospital)
1984 Senior Registrar, Microbiology (Fremantle Hospital)
1983 Senior Registrar, General Medicine and Gastroenterology (Fremantle Hospital)
1982 General Physician and Acting Superintendent (Port Hedland Regional Hospital)
1982 Registrar, Haematology (Royal Perth Hospital)
1981 Registrar, General Medicine and Gastroenterology (Royal Perth Hospital)
1980 Registrar, Neurology and Geriatrics (Royal Perth Hospital)
1979 Registrar, Intensive Care and General Medicine (Royal Perth Hospital)
1977-78 Registrar General Medicine (Sir Charles Gairdner Hospital)
1976 Resident Medical Officer (Sir Charles Gairdner Hospital)
1975 Internship (Sir Charles Gairdner Hospital, Perth WA)
1968-74 Bachelor of Medicine and Bachelor of Surgery (MBBS) University of Western Australia
1969-71 Citizen Military Forces, Western Australia
1960-68 Marist Brothers College, Perth, Western Australia
Positions
● Nobel Laureate
● UWA Brand Ambassador
● Director UWA Marshall Centre for Infectious Diseases Research and Training; Helicobacter Research Laboratory
● Ambassador for Life Sciences for Western Australia
● Ambassador for Life Sciences for Henan
● Founder and Director of ONDEK, a biotechnology company
● Founder of TRI-MED, a diagnostics company
● Co-founder of Hongmed Infagen, a diagnostics company
● Director of Marshall International Digestive Diseases Hospital, Zhengzhou
● Director of Marshall Lab for Biomedical Engineering, Shenzhen University
Awards
2023 The Chinese International Science and Technology Cooperation Award
2015 China Friendship Award, China’s highest honour to foreign experts
The Friendship Award is a state level award set up to thank and commend outstanding foreign experts annually for their great contribution to China’s social development and economic, scientific, technological, educational and cultural construction
2011 ASMR Medalist
2011 Foreign Member of Chinese Academy of Engineering, Beijing
CAE pays respect to Barry’s outstanding achievements in engineering and technological sciences as well as his remarkable contributions to China’s development. Every year 19 very prestigious scientists from around the world are nominated but only 6 are chosen. Barry is one a few from Australia to ever be recognised
2009 Galen Medal, Society of Apothecaries
2008 Lennon K. Black Prize for Excellence in Biomedical Research, Jefferson College of Graduate Studies, USA
2007 Western Australian of the Year (shared with Dr J R Warren)
2006 Western Australian Citizen of the Year (shared with Dr J R Warren)
2006 The William Beaumont Prize – AGA USA
2005 The Nobel Prize for Physiology or Medicine (shared with Dr J Warren)
2003 The Bulletin Smartest 100 – Health & Medicine Winner
2003 Silver Seal – University of Bologna, Italy
2003 Australian Centenary Medal
2001 Prince Mahidol Award 2001 in the field of Public Health - joint winner, Bangkok, Thailand
2001 Clunies Ross National Science and Technology Award, Canberra, Australia
1999 Benjamin Franklin Medal for Life Science, The Franklin Institute, Philadelphia USA
1998 Buchanan Medal, The British Royal Society of Medicine
1998 Florey Medal, Canberra
1998 Dr. A.H. Heineken Prize for Medicine, The Alfred Heineken Fondsen Foundation, Amsterdam
1998 Australian Achiever Award
1997 Kilby Prize, The Kilby Foundation, Dallas
1997
Paul Ehrlich Prize, Paul Ehrlich Institute, Frankfurt, Germany DM$50,000 (shared with Dr J R Warren)
Theory and Practice: Innovation and Curiosity Driven Research
Barry James Marshall
University of Western Australia (UWA)
Helicobacter pylori remains a critical public health concern, particularly in China, where the prevalence of gastric cancer is high, and antibiotic resistance is a growing challenge. The eradication of H. pylori is essential to reduce the incidence of gastric cancer and improve patient outcomes. Precision medicine has emerged as a promising approach to address these issues, enabling tailored treatment strategies based on individual patient profiles. A notable advancement in this field is combining the string test, an established diagnostic method, with quantitative PCR (qPCR) technology. This innovative diagnostic device not only detects the presence or absence of H. pylori but also provides detailed information on the antibiotic resistance profile of the bacteria. The integration of these technologies offers a low-cost, efficient solution for healthcare providers, facilitating precise and personalized treatment plans. By accurately identifying antibiotic-resistant strains of H. pylori, this approach allows for the selection of the most effective antibiotics, thereby reducing the risk of treatment failure and further resistance development. The implementation of such diagnostic tools in clinical practice can significantly lower healthcare costs and enhance the effectiveness of H. pylori eradication programs. Overall, the adoption of precision medicine, supported by advanced diagnostic technologies like the string test and qPCR, represents a crucial step forward in combating antibiotic-resistant H. pylori infections and mitigating the burden of gastric cancer in high-risk populations.
